IGC Pharma (FRA:IGS1) 3-Year EBITDA Growth Rate : 7.50% (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma 3-Year EBITDA Growth Rate?

IGC Pharma's EBITDA per Share for the three months ended in Sep. 2024 was €-0.02.

During the past 3 years, the average EBITDA Per Share Growth Rate was 7.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -5.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -3.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of IGC Pharma was 115.90% per year. The lowest was -115.60% per year. And the median was 13.55% per year.

Competitive Comparison of IGC Pharma's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, IGC Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGC Pharma's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where IGC Pharma's 3-Year EBITDA Growth Rate falls into.

IGC Pharma 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

IGC Pharma (FRA:IGS1) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

IGC Pharma 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of IGC Pharma's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

IGC:USA IGS1:Germany

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma Headlines

No Headlines